Key points are not available for this paper at this time.
Our cohort showed a low rate of immunogenicity to VDZ and an association between VTLs and CRP in CD but not in UC patients. No relationship between VTLs and MH was detected. Vedolizumab trough level measurements altered management in approximately three fourths of patients.
Al‐Bawardy et al. (Fri,) studied this question.